Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in unresectable hepatocellular carcinoma
NCT05432492Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2022
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc. Primary endpoints: Number of patients with Adverse Events at 2 years, Objective Response Rate Per RECIST v1.1 at 2 years and 1 more. Started Aug 2022; status: completed.
02
Drugs
ivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05432492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432492.